Claude T. Berge
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis.
Journal: Annals of clinical and translational neurology
Published: May 23, 2025
AI-driven reclassification of multiple sclerosis progression.
Journal: Nature medicine
Published: October 29, 2024
Futility Interim Analyses - A Plea for Simplicity.
Journal: Therapeutic innovation & regulatory science
Published: August 30, 2024
A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies.
Journal: Pharmaceutical statistics
Published: March 18, 2020
Current insights in the pathogenesis of scleritis.
Journal: Experimental eye research
Published: January 30, 2020
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.
Journal: Advances in therapy
Published: July 04, 2017
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Haematology
Published: January 13, 2017
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.
Journal: Leukemia & lymphoma
Published: June 25, 2016
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Journal: The Lancet. Oncology
Published: February 14, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026